Everence Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) during the first quarter, Holdings Channel reports. The institutional investor purchased 8,430 shares of the specialty pharmaceutical company’s stock, valued at approximately $272,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in SUPN. Tudor Investment Corp Et Al lifted its position in shares of Supernus Pharmaceuticals by 535.2% during the third quarter. Tudor Investment Corp Et Al now owns 68,597 shares of the specialty pharmaceutical company’s stock worth $1,829,000 after acquiring an additional 57,797 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Supernus Pharmaceuticals by 3.0% during the 3rd quarter. California State Teachers Retirement System now owns 69,837 shares of the specialty pharmaceutical company’s stock worth $1,863,000 after purchasing an additional 2,038 shares in the last quarter. Voloridge Investment Management LLC bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth about $1,704,000. Exchange Traded Concepts LLC grew its holdings in Supernus Pharmaceuticals by 1.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 46,635 shares of the specialty pharmaceutical company’s stock valued at $1,360,000 after buying an additional 813 shares in the last quarter. Finally, Frontier Capital Management Co. LLC increased its position in shares of Supernus Pharmaceuticals by 6.7% during the fourth quarter. Frontier Capital Management Co. LLC now owns 617,701 shares of the specialty pharmaceutical company’s stock valued at $18,012,000 after buying an additional 38,628 shares during the period.
Shares of NASDAQ SUPN opened at $27.76 on Thursday. The company has a current ratio of 2.00, a quick ratio of 1.69 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average of $27.92 and a 200-day moving average of $29.73. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 21.35 and a beta of 1.12. Supernus Pharmaceuticals, Inc. has a 12 month low of $23.15 and a 12 month high of $34.50.
SUPN has been the topic of a number of analyst reports. StockNews.com raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 18th. TheStreet lowered shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, April 18th.
Supernus Pharmaceuticals Company Profile (Get Rating)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.